Ipsen Pharma S.a.s.

Ipsen Pharma

Jeanne Mary Comstock

Zheng Xin Dong

Daniel B Deoliveira

Sun H Kim

Michael DeWitt Culler

Yeelana Shen

Jundong Zhang

Yeelena Shen

Nicholas C Prairie

Maria L Ufret

Deborah M Rothman

Deborah Rothman

Michael Dewitt Culler

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.

Melanocortin receptor ligands modified with hydantoin

The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.

Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59

The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.

Peptide vectors

The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below: wherein the definitions of Ato Aand Rto Rare provided for in the specification for each of formulae (I) and (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising an effective amount of a compound of formula (I), that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.

Analogs of ghrelin

Growing community of inventors

West Boylston, MA, United States of America

Jeanne Mary Comstock